These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 21480193)

  • 1. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
    Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
    Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing.
    Trexler-Schmidt M; Sargis S; Chiu J; Sze-Khoo S; Mun M; Kao YH; Laird MW
    Biotechnol Bioeng; 2010 Jun; 106(3):452-61. PubMed ID: 20178122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacture of pharmaceutical proteins from hybridomas and other cell substrates.
    Tolbert WR; Rupp RG
    Dev Biol Stand; 1989; 70():49-56. PubMed ID: 2503410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using partition designs to enhance purification process understanding.
    Pieracci J; Perry L; Conley L
    Biotechnol Bioeng; 2010 Dec; 107(5):814-24. PubMed ID: 20632374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives.
    Singh N; Arunkumar A; Chollangi S; Tan ZG; Borys M; Li ZJ
    Biotechnol Bioeng; 2016 Apr; 113(4):698-716. PubMed ID: 26302443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparability assessments of process and product changes made during development of two different monoclonal antibodies.
    Lubiniecki A; Volkin DB; Federici M; Bond MD; Nedved ML; Hendricks L; Mehndiratta P; Bruner M; Burman S; Dalmonte P; Kline J; Ni A; Panek ME; Pikounis B; Powers G; Vafa O; Siegel R
    Biologicals; 2011 Jan; 39(1):9-22. PubMed ID: 20888784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational and systematic protein purification process development: the next generation.
    Nfor BK; Verhaert PD; van der Wielen LA; Hubbuch J; Ottens M
    Trends Biotechnol; 2009 Dec; 27(12):673-9. PubMed ID: 19815300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated continuous production of recombinant therapeutic proteins.
    Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
    Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current state-of-the-art in plant-based antibody production systems.
    Donini M; Marusic C
    Biotechnol Lett; 2019 Mar; 41(3):335-346. PubMed ID: 30684155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of vibrational spectroscopy to the structural characterization of monoclonal antibody and its aggregate.
    Li CH; Li T
    Curr Pharm Biotechnol; 2009 Jun; 10(4):391-9. PubMed ID: 19519414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a multi-product leached protein A assay for bioprocess samples containing recombinant human monoclonal antibodies.
    Ren D; Darlucio MR; Chou JH
    J Immunol Methods; 2011 Mar; 366(1-2):20-7. PubMed ID: 21315722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality.
    Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexibility--the guiding principle for antibody manufacturing.
    Carson KL
    Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.